Catalogue

Background
Complement Receptor-1 (CR-1), CD35 complex is four different allotypes (C,A,B,D) C is 160 kDa; A is 190 kDa; B is 220 kDa and D is 250 kDa. It is involved in the processing of immune complexes, promoting of binding and phagocytosis of C3b complexes and inhibition of complement activation. CR-1 is on neutrophils, eosinophils, monocytes, B-cells, some NK-cells, erythrocytes, myeloid leukemias, follicular dendritic reticulum cells and is negative on basophils.

Synonyms: CD35 FITC

Source

Immunogen: CD35=Derived from the hybridization od mouse SP2/0 cells with spleen cells of mice immunized with purified CR1

Product

Product Form: FITC

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein

Purification Method: Protein A/G Chromatography

Concentration: Titered for flow cytometry

Applications
PBMC: Add10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2° to 8°C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add 10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature (20°C). Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer?s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.

Functional Analysis: Flow Cytometry Staining

Storage
Product should be stored at 4-8°C. DO NOT FREEZE

Product Stability: See expiration date on vial

Shipping Conditions: Room Temperature

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C J Immunol 1991 Mar 1;146(6):1766-72 2. The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera. Moulds JM; Nickells MW; Moulds JJ; Brown MC; Atkinson JP J Exp Med 1991 May ;173(5):1159-63 3. Deduction from Wilms' tumour that glomerular podocytes produce the basement membrane material bearing Goodpasture determinants. Droz D; Diebold N; Jan D; Jaubert F J Pathol 1990 De;162(4):323-7 4. Purification and characterization of IgG immunoconglutinins from patients with systemic lupus erythematosus: implications for a regulatory function. Nilsson B; Ekdahl KN; Svarvare M; Bjel Clin Exp Immunol 1990 No;82(2):262-7 5. Granulocyte-macrophage colony-stimulating factor increases synthesis and expression of CR1 and CR3 by human peripheral blood neutrophils. Neuman E; Huleatt JW; Jack RM J Immunol 1990 Nov 1;145(10):3325-32 6. Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Appay MD; Kazatchkine MD; Levi-Strauss M; Hinglais N; Bariety J Kidney Int 1990 Au;38(2):289-93 7. Complement receptor type 1 (C3b/C4b receptor; CD35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21). Fearon DT; Ahearn JM Curr Top Microbiol Immunol 1990;153 p83-98

Protein Reference(s)

Database Name: UniProt

Accession Number: P17927

Safety Datasheet(s) for this product: